[11C]AZ14132516

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Crohn DiseaseCrohn's DiseaseHealthy Volunteers

Early Phase 1

A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants

CompletedNCT05818514

AstraZenecaHealthy Volunteers

Start: 2023-04-27End: 2023-07-11Updated: 2023-07-14

Phase 1

Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

CompletedNCT06053424

AstraZenecaCrohn's Disease

Start: 2023-09-25End: 2024-10-08Updated: 2025-08-27

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

CompletedNCT06432764

AstraZenecaCrohn Disease

Start: 2024-10-16End: 2026-03-27Updated: 2026-04-14

Related Papers

P1116 Imaging of CCR9 in the small bowel of patients with Crohn’s disease: effects of the CCR9-depleting monoclonal antibody AZD7798

Journal of Crohn s and Colitis2025-01-011 citations

P0506 AZD7798, a monoclonal antibody depleting CCR9+ T cells, with the potential to target hard-to-treat small bowel Crohn’s disease

Journal of Crohn s and Colitis2025-01-01

P014 First-time-in-human visualisation of CCR9 expression in the gut by positron emission tomography

Journal of Crohn s and Colitis2024-01-01